What risks do you advise in premenopausal patients with history of higher risk hormone positive breast cancer patients, who require fertility treatments and injections?

Community
Company
News
Contact Us
Sign in

Topics: Breast Cancer • Medical Oncology • Breast Cancer, Non-metastatic • hormone receptor +

In practice, when do you feel comfortable stopping endocrine therapy to allow pregnancy?

Related Questions

How do you approach ovarian function suppression in premenopausal women with HR+/HER2-, node negative breast cancer and intermediate OncoType dx scores (11-25) who received chemotherapy?

For which patients, if any, do you typically order additional imaging workup for staging in early-stage breast cancer?

Would you avoid chemotherapy in a postmenopausal woman (age 65+) with HR+/HER2 negative, breast cancer, T3, with Oncotype DX < 25?

Would you offer systemic therapy (TH) to a patient with HER2+ (3+), HR- high grade microinvasive breast cancer with single focus or multifocal?

How do you treat a patient with TNBC, BRCA WT, who received KEYNOTE 522 with residual disease post neoadjuvant therapy?

What is your treatment approach in patients with early breast cancer with axillary soft tissue involvement, with or without concurrent lymph node involvement?

Would you consider HRT after risk-reducing salpingo-oophorectomy for a young (mid-30s) patient with BRCA1 and a history of TNBC?

Would you ever consider managing HR+ DCIS non-surgically?

Is there a role for adjuvant pembrolizumab/capecitabine in a patient with TNBC who receives neoadjuvant AC-T with residual disease found at time of surgery?

In light of the NSABP B51 data presented at SABCS, will you defer RNI in all patients with negative nodes after chemotherapy?